Abbott Laboratories faces a critical product safety issue following an FDA report on December 23, 2025, linking its Freestyle Libre Plus Continuous Glucose Monitor to seven patient deaths and over 700 injuries due to false low glucose readings. This news emerges shortly after the company announced FDA approval on December 22 for its Volt™ PFA System for AFib treatment, expanding its cardiovascular portfolio. Separately, Abbott also increased its quarterly common dividend by 6.8% to $0.63 per share. On December 29, ABT shares are up 0.46% at $125.42, showing minor movement in a broader market that is trading lower.